No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets. The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP). Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.
www.clinuvel.comNo one on the platform currently holds CUV.AX.
No tracked institution reports a position in CUV.AX as of their last filing.
No one on the platform has traded CUV.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 11.3% | 81.2% | 178.0% | — | — | — |
| Rev. Growth % | -1.0% | 14.4% | ||||
| Profit Margin % | 36.1% | 37.1% | 44.1% | |||
| Free Cash Flow Margin % | 37.6% | 44.4% | 46.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $95M | -2.4% | $0.68 | $0.60–$0.79 | — | 6 |
| 2028 | $101M | +6.7% | $0.71 | $0.51–$0.96 | — | 6 |
| 2029 | $139M | +36.9% | $1.02 | $0.40–$2.42 | — | 6 |
| 2030 | $377M | +171.9% | $3.94 | $2.98–$6.19 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-26 | $0.48 | $0.45 | -6.1% |
| 2026-02-25 | $0.29 | $0.21 | -29.5% |
| 2025-08-27 | $0.28 | $0.44 | +56.4% |
| 2025-02-26 | $0.22 | $0.28 | +29.0% |
| 2024-08-29 | $0.44 | $0.49 | +11.1% |
| 2024-02-22 | $0.26 | $0.21 | -17.7% |
| 2023-08-30 | $0.37 | $0.37 | +0.6% |
| 2023-02-23 | $0.25 |
| $0.22 |
| -11.1% |
| +0.00% |
| $111M |
| — |
| HLS.AXHealius Limited | $0.45 | -2.20% | $323M | — |
| IMM.AXImmutep Limited | $0.05 | +4.44% | $69M | — |
Source: Financial Modeling Prep · peers by sector/industry